This inventor holds 1 USPTO granted patent. Top assignee: Johnson and Johnson Vision Care, Inc.. Active years: 2017.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017
Title: Arthur H Shedden, Jr: Innovator in Myopia Control Optics
Introduction
Arthur H Shedden, Jr. is a notable inventor based in Jacksonville, FL (US). He has made significant contributions to the field of ophthalmic devices, particularly in the area of myopia control. His innovative work focuses on integrating therapeutic agents with optical solutions to address the growing concern of myopia.
Latest Patents
Arthur H Shedden, Jr. holds a patent for a lens incorporating myopia control optics and muscarinic agents. This patent describes a novel approach to ophthalmic devices, such as contact lenses, which combine myopia control optics with therapeutic agents known to manage myopia. The invention aims to create a drug delivery mechanism that can inhibit or arrest the progression of myopia in individuals. The patent includes the use of various contact lenses that may incorporate therapeutic agents like atropine, atropine sulphate monohydrate, and/or pirenzepine.
Career Highlights
Arthur is currently associated with Johnson and Johnson Vision Care, Inc., where he continues to develop innovative solutions in vision care. His work has been instrumental in advancing the understanding and treatment of myopia, contributing to better eye health for many individuals.
Collaborations
Arthur has collaborated with Khaled A Chehab, working together to enhance the effectiveness of myopia control technologies. Their partnership has led to advancements in the field, showcasing the importance of teamwork in innovation.
Conclusion
Arthur H Shedden, Jr. is a pioneering inventor whose work in myopia control optics is making a significant impact in the field of ophthalmology. His innovative approach to combining therapeutic agents with optical devices represents a promising advancement in the treatment of myopia.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
